Arca
Skip to content

Glioblastoma

Drug research and approvals for glioblastoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 320 studies of glioblastoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 48 drug trials for it since 2013, FDA has 3 approved and 79 open orphan designations naming it, and the EU has 5 authorised medicines for it.

  • Recruiting worldwide: 320
  • Trials authorized in Canada: 48
  • FDA orphan approvals: 3
  • EU medicines: 5

Recruiting Now

Newest start dates first, of 320 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 48; search them all in Canada trials
Oct 16, 2026Novel endovascular therapy with bevacizumab and cannabinoids for glioblastomaAVASTIN / SATIVEX / OSMITROL INJECTION 20%ST MICHAELS HOSPITALPending
Oct 1, 2026A phase 1 safety and feasibility trial of focused ultrasound for the treatment of high-grade glioma in patients undergoing standard chemotherapy (gb7260)PERFLUTREN (PERFLUOROPROPANE)SUNNYBROOK RESEARCH INSTITUTEPending
Mar 20, 2025A phase 1/2 study to assess bdtx-1535, an oral egfr inhibitor, in patients with glioblastoma or non-small cell lung cancerSILEVERTINIB (BDTX-1535)BLACK DIAMOND THERAPEUTICS, INC.Ongoing
Nov 15, 2024A phase 3, randomized, double-blind, placebo-controlled study of optune® (ttfields, 200 khz) concomitant with maintenance temozolomide and pembrolizumab versus…PEMBROLIZUMABNOVOCURE GMBHOngoing
Oct 16, 2024A phase 3, open-label, randomized 2-arm study comparing the clinical efficacy and safety of niraparib with temozolomide in adult participants with…NIRAPARIBNEUROTRIALS LLCOngoing
Jan 12, 2024Fet-pet/mri based treatment planning for glioblastoma multiforme in post-surgical patientsO-(2-[18F]-FLUOROETHYL)-L-TYROSINE ([18F] FET)SUNNYBROOK RESEARCH INSTITUTEPending
Aug 1, 2023A randomized phase II study on intra-arterial carboplatin combined with caelyx compared to intra-arterial carboplatin combined with etoposide phosphate for…DOXORUBICIN / CARBOPLATIN / ETOPOSIDE PHOSPHATECIUSSS DE L'ESTRIE - CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKEOngoing
Apr 20, 2023Study of opdualag (novolumab and relatlimab) in relapsed hypermutant glioblastoma: a pediatric oncology precision medicine studyOPDUALAGC17 COUNCILClosed
Dec 1, 2022A phase III trial of lomustine-temozolomide combination therapy versus standard temozolomide in patients with methylated mgmt promoter glioblastomaLOMUSTINENRG ONCOLOGYClosed
Jun 23, 2022A pivotal study to evaluate the safety and effectiveness of exablate model 4000 using microbubble resonators to temporarily mediate blood-brain barrier…PERFLUTRENInsightecPending

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 82
May 5, 2009AvastinTreatment of glioblastoma with progressive disease following prior therapyGenentech, Inc.Approved
Mar 15, 2005TemodarTreatment of adult patients with newly diagnosed glioblastoma multiforme concomitatly with radiotherapy and then as maintenance treatmentSchering-Plough Research InstituteApproved
Sep 23, 1996GliadelAs an adjunct to surgery to prolong survival in patients with recurrent glioblastoma multiforme for whom surgical resection is indicatedGuilford Pharmaceuticals, Inc.Approved
Oct 16, 2025tinostamustinetreatment of glioblastomaKnoa Pharma LLCDesignated
Jul 11, 2025cintredekin besudotox (CB)treatment of malignant glioma (glioblastoma multiforme)Precision NeuromedDesignated
Feb 13, 2025FGFR3 targeting antibody-drug conjugatetreatment of glioblastoma, glioma (harboring the FGFR3-TACC3 fusion)Biohaven Therapeutics Ltd.Designated
Nov 18, 2024honokioltreatment of glioblastoma multiforme (GBM)Chengdu Jinrui Foundation Biotechnology Co., Ltd.Designated
Sep 10, 2024temozolomidetreatment of glioblastoma multiforme in pediatric patientsAccord Healthcare IncDesignated
Jul 25, 2023Maytansine bound via linker to bacterial derived,…Treatment of Glioblastoma MultiformeCyGenica Ltd.Designated
Jun 21, 2023(7S)-N-(3-bromo-2-fluorophenyl)-7-[(4-methylpiperazin-1-yl)m…Treatment of glioblastomaKatmai PharmaceuticalsDesignated
Mar 1, 2023Autologous CD34+ cell enriched haematopoietic stem and…Treatment of glioblastoma multiformeGenenta SciencesDesignated
Feb 27, 2023Gallium maltolateTreatment of glioblastomaImaging Biometrics, LLCDesignated
Feb 14, 2023(-)-B-ElemeneTreatment of Glioblastoma MultiformeSichuan Honghe Biotechnology Co., Ltd.Designated
Jan 25, 2023Degrader of Lysine-specific histone demethylase 1A and REST…Treatment of GlioblastomaBeactica Therapeutics ABDesignated
Jan 18, 2023(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-…Treatment of Glioblastoma (GBM)Jubilant Therapeutics Inc.Designated

Medicines Authorised in the EU

Newest first
Jul 13, 2011Temozolomide Suntemozolomide · genericSun Pharmaceutical Industries Europe B.V.EMA ↗
Mar 15, 2010Temozolomide Accordtemozolomide · genericAccord Healthcare S.L.U.EMA ↗
Jan 28, 2010Temozolomide Tevatemozolomide · genericTeva B.V.EMA ↗
Jan 25, 2010Temomedactemozolomide · genericmedac Gesellschaft für klinische Spezialpräparate mbHEMA ↗
Jan 26, 1999TemodaltemozolomideMerck Sharp & Dohme B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.